Abstract:Therapy with immune checkpoint inhibitors (ICIs) has improved overall survival and cancer-related morbidity of cancer treatment even in cancer entities with poor prognosis. Since the approval of the first ICI, ipilimumab, for treatment of advanced melanoma by the Food and Drug Administration (FDA) in 2011, the spectrum of indications and approved ICIs has grown, rapidly. Up to now, seven different ICIs for more than 20 indications are available. However, their mechanisms of action can lead to immune-related adverse events (irAEs). In particular, neurological irAEs are clinically relevant. Although they are rare, an early and accurate diagnosis is challenging and neurological disease course and sequelae are potentially fatal. Between 08/2017 and 03/2020, 31 patients received ICI treatment at Hannover Medical School and presented with neurological adverse events (N-irAEs). Treated malignancies were metastatic melanoma, bronchial carcinoma, and urothelial cell carcinoma. All patients received comprehensive neurological diagnostics including clinical examination and magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) analysis was obtained in 21 patients and electroneurography was performed in 22 patients. Although N-irAEs were suspected in all 31 patients, 11 patients had other conditions leading to neurological symptoms including tumor metastases in seven patients and hemorrhagic or ischemic stroke in four patients. In the following, these patients are referred to as the differential diagnosis (DD) group. Patients with N-irAEs suffered from immune mediated neuropathy (9/20), myositis and/or myasthenic syndrome (6/20), or encephalitis/cerebellitis (5/20). Except for cell count, CSF results did not differ between the N-irAEs and the DD group. Symptoms related to N-irAEs are rather unspecific potentially mimicking other tumor-related symptoms such as metastases. Patients with malignancy are predominantly not treated by neurologists. Because of the complexity of neurological symptoms, detailed neurological investigations in specialized institutions are necessary in patients with new neurological symptoms and need to be critically discussed with treating oncologists.

Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature

Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review

Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report

Nivolumab-Induced Neuromyopathy: A Case Report

Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook

Inflammatory Reaction Secondary to Immune Checkpoint Inhibitor Therapy Mimicking a Post-Operative Brain Abscess

Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy

Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature

Mortality associated with the development of acute liver failure after a single dose of nivolumab

PD-1-induced Encephalopathy: a Report of 2 Cases on Neurological Toxicities with Immune Checkpoint Inhibitors.

Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer

Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature

Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature

Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy

Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report

Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management

Neurosarcoidosis following Immune Checkpoint Inhibition